The elevated creatine kinase level of 12,400 U/L is the most specific differentiating factor

Because CK elevation occurs exclusively in neuroleptic malignant syndrome and is never seen in serotonin syndrome. Rhabdomyolysis is a pathognomonic feature of NMS that results from sustained muscle rigidity caused by dopaminergic blockade in the basal ganglia. Serotonin syndrome produces hyperkinetic movements that do not generate sufficient muscle damage to elevate CK levels. Therefore, any CK elevation above 1,000 U/L definitively confirms NMS over serotonin syndrome. While markedly elevated CK is more characteristic of NMS, it is incorrect to state that CK elevation never occurs in serotonin syndrome. Severe serotonin syndrome can also produce muscle rigidity, clonus, and rhabdomyolysis with elevated CK levels, though typically to a lesser degree than NMS.

The fever of 104.2 degrees Fahrenheit is the most distinguishing feature

Because serotonin syndrome does not produce significant temperature elevations. Hyperthermia in NMS results from disrupted hypothalamic thermoregulation due to central dopamine blockade, a mechanism unique to antipsychotic exposure. Serotonin syndrome typically presents with mild temperature elevations that rarely exceed 100.4 degrees Fahrenheit. The degree of fever directly correlates with the severity of NMS and is the most reliable way to differentiate the two syndromes. This is incorrect because severe serotonin syndrome can produce significant hyperthermia, sometimes exceeding 106 degrees Fahrenheit. Both NMS and serotonin syndrome can cause life-threatening hyperthermia through different mechanisms.

The lead-pipe muscle rigidity is the most specific differentiating finding between NMS and serotonin syndrome

NMS characteristically produces generalized lead-pipe rigidity due to dopamine D2 receptor blockade in the nigrostriatal pathway, resulting in sustained tonic muscle contraction. In contrast, serotonin syndrome typically presents with neuromuscular hyperactivity manifesting as clonus, hyperreflexia, and myoclonus rather than continuous tonic rigidity. This distinction in the quality of neuromuscular findings is the most reliable clinical feature for differentiating these two hyperthermic syndromes at the bedside. Lead-pipe rigidity is the hallmark neuromuscular finding of NMS, resulting from dopaminergic blockade in the basal ganglia that produces sustained tonic muscle contraction.

The leukocytosis with a WBC of 14,800/uL is the most specific differentiating factor

Because white blood cell elevation is a unique laboratory marker of NMS that does not occur in serotonin syndrome. Leukocytosis in NMS reflects the systemic inflammatory response triggered by massive muscle breakdown and dopamine receptor blockade in the hypothalamus. Serotonin syndrome does not activate the immune system in this manner and typically presents with normal white blood cell counts. An elevated WBC in the setting of hyperthermia and altered mental status should prompt immediate consideration of NMS over serotonin syndrome. While leukocytosis is commonly seen in NMS, it is not specific to this condition and cannot reliably differentiate NMS from serotonin syndrome.